187 related articles for article (PubMed ID: 24414130)
21. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
Schrijver WAME; Suijkerbuijk KPM; van Gils CH; van der Wall E; Moelans CB; van Diest PJ
J Natl Cancer Inst; 2018 Jun; 110(6):568-580. PubMed ID: 29315431
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
23. The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer.
Qu Q; Zong Y; Fei XC; Chen XS; Xu C; Lou GY; Shen KW
World J Surg Oncol; 2014 Apr; 12():93. PubMed ID: 24721777
[TBL] [Abstract][Full Text] [Related]
24. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
25. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
28. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
29. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
30. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
31. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
Kaidar-Person O; Meattini I; Jain P; Bult P; Simone N; Kindts I; Steffens R; Weltens C; Navarria P; Belkacemi Y; Lopez-Guerra J; Livi L; Baumert BG; Vieites B; Limon D; Kurman N; Ko K; Yu JB; Chiang V; Poortmans P; Zagar T
Breast Cancer Res Treat; 2018 Jan; 167(2):479-483. PubMed ID: 28975433
[TBL] [Abstract][Full Text] [Related]
32. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
[No Abstract] [Full Text] [Related]
33. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
34. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
van Es SC; van der Vegt B; Bensch F; Gerritse S; van Helden EJ; Boon E; Angus L; Overbosch J; Menke-van der Houven van Oordt CW; Verheul HM; van Herpen CML; Jager A; Oosting SF; de Vries EGE; Schröder CP
Am J Surg Pathol; 2019 Oct; 43(10):1355-1360. PubMed ID: 31283631
[TBL] [Abstract][Full Text] [Related]
35. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
[TBL] [Abstract][Full Text] [Related]
37. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.
Idirisinghe PK; Thike AA; Cheok PY; Tse GM; Lui PC; Fook-Chong S; Wong NS; Tan PH
Am J Clin Pathol; 2010 Mar; 133(3):416-29. PubMed ID: 20154280
[TBL] [Abstract][Full Text] [Related]
38. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?
Sighoko D; Liu J; Hou N; Gustafson P; Huo D
Oncologist; 2014 Jun; 19(6):592-601. PubMed ID: 24807915
[TBL] [Abstract][Full Text] [Related]
39. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
40. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]